{
    "organizations": [],
    "uuid": "c09b39bc06f3e4aa5a05a4cb54e9f5df4aff9eae",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-lysogene-gets-green-light-from-eur/brief-lysogene-gets-green-light-from-european-medicines-agency-on-mps-iiia-pivotal-study-idUSFWN1PW114",
    "ord_in_thread": 0,
    "title": "BRIEF-Lysogene Gets Green Light From European Medicines Agency On MPS IIIA Pivotal Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 6 (Reuters) - LYSOGENE SA:\n* LYSOGENE GETS PIP GREEN LIGHT FROM EUROPEAN MEDICINES AGENCY ON MPS IIIA PIVOTAL STUDY; PAVING WAY FOR CLINICAL TRIAL APPLICATION APPROVALS\n* ‍SUCCESSFUL PIP COMPLIANCE CHECK EXTENDS MARKET EXCLUSIVITY TO 12 YEARS AT EU MARKET AUTHORIZATION​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-07T00:54:00.000+02:00",
    "crawled": "2018-02-07T22:13:43.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "lysogene",
        "sa",
        "lysogene",
        "get",
        "pip",
        "green",
        "light",
        "european",
        "medicine",
        "agency",
        "mp",
        "iiia",
        "pivotal",
        "study",
        "paving",
        "way",
        "clinical",
        "trial",
        "application",
        "approval",
        "pip",
        "compliance",
        "check",
        "extends",
        "market",
        "exclusivity",
        "year",
        "eu",
        "market",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}